What is it about?
To investigate whether neurofilament light polypeptide (NfL) level in cerebrospinal fluid (CSF), currently a prognostic biomarker of neurodegeneration in patients with multiple sclerosis (MS), may be a potential biomarker of cognitive dysfunction in MS.
Featured Image
Why is it important?
This study provides preliminary evidence for an association between CSF NfL levels and cognition in progressive forms of MS, which requires validation in larger samples.An inversely proportional association between CSF NfL levels and BICAMS z-scores was found in progressive forms of MS (rp = -0.944).
Perspectives
Read the Original
This page is a summary of: Does cognitive dysfunction correlate with neurofilament light polypeptide levels in the CSF of patients with multiple sclerosis?, Journal of International Medical Research, April 2019, SAGE Publications,
DOI: 10.1177/0300060519840550.
You can read the full text:
Contributors
The following have contributed to this page